Bernstein Upgrades Vertex Pharmaceuticals to Outperform, Predicting an 8.01% Upside

Bernstein upgraded Vertex Pharmaceuticals (VRTX) from Market Perform to Outperform. The average one-year price target is $501.03/share, a 8.01% increase from its latest closing price of $463.86/share. The projected annual revenue is 10,721MM, a decrease of 8.55%, and the projected annual non-GAAP EPS is 19.52. Institutions own 300,746K shares, a 2.97% decrease in the last three months.